Kosé is partnering with I Peace, Inc. and Reju, Inc. to develop personalized beauty products comprising iPSF (an induced pluripotent stem [iPS] cell extract) derived from customers’ own blood-drawn cells.
This process will reportedly optimize dosages and textures for each consumer; finished products will reportedly be “provided through medical institutions under medical supervision,” per Kosé.
By the end of 2024, iPSF-based formulations will commence demonstrating testing in Japan.
LIVE & HYBRID All you need to know about preclinical and clinical testing is at…
Abstract Background Oxidative stress is a significant factor in skin aging and pigmentation, which can be precipitated…
Remote prescribing of cosmetic injectables is set to be banned within weeks in a landmark…